title: Clinical features and treatment outcomes of Hodgkin's lymphoma in Hong Kong Chinese.
abstract: BACKGROUND
  Little information is available on the outcomes of Hodgkin's lymphoma in Chinese patients. We analyzed the clinical and histopathological characteristics, treatment types, clinical course and treatment outcomes of Hong Kong Chinese patients.
  
  
  METHODS
  Patients with Hodgkin's lymphoma diagnosed from January 1991 to December 2010 were recruited. A retrospective analysis of these patients was performed.
  
  
  RESULTS
  Sixty-seven Chinese patients (38 males and 29 females) were identified and the median age was 36 (range 16-80). Nodular sclerosis was the most common histology (54%), followed by mixed cellularity (36%). Twenty-four patients had early favorable, 20 patients had early unfavorable and 23 patients had advanced-stage diseases. The most common presentation was palpable lymph node or mass (85%) followed by fever, weight loss, night sweating and mediastinal mass. Ninety percent of patients received chemotherapy and 40% received radiotherapy as consolidation. Seven patients with stage I lymphoma received radiotherapy alone. ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) was the most commonly used chemotherapeutic regimen. Following treatment, 87% of patients achieved complete remission. Six patients relapsed after first remission and 3 achieved second remission after re-induction therapy. The 5-year overall survival of the entire cohort was 89% and the freedom from treatment failure (FFTF) at 5 years was 82%. The 5-year overall survival rate for early favorable, early unfavorable and advanced stages was 95.7%, 95.0% and 74.7%, respectively.
  
  
  CONCLUSIONS
  Despite the relatively low incidence of Hodgkin's lymphoma in Hong Kong Chinese, the treatment outcomes are comparable to Caucasian patients.
authors.affiliation: Department of Medicine, Tuen Mun Hospital, Shatin, Hong Kong ; Department of Medicine and Therapeutics, Prince of Wales Hospital, the Chinese University of Hong Kong, Shatin, Hong Kong.
authors.forename: Man Fai
authors.initials: MF
authors.lastname: Law
authors.affiliation: Departments of Oncology, Tuen Mun Hospital, Shatin, Hong Kong.
authors.forename: Ting Ying
authors.initials: TY
authors.lastname: Ng
authors.affiliation: Department of Medicine, Tuen Mun Hospital, Shatin, Hong Kong.
authors.forename: Hay Nun
authors.initials: HN
authors.lastname: Chan
authors.affiliation: Department of Medicine, Tuen Mun Hospital, Shatin, Hong Kong.
authors.forename: Ho Kei
authors.initials: HK
authors.lastname: Lai
authors.affiliation: Department of Medicine, Tuen Mun Hospital, Shatin, Hong Kong.
authors.forename: Chung Yin
authors.initials: CY
authors.lastname: Ha
authors.affiliation: Departments of Pathology, Tuen Mun Hospital, Shatin, Hong Kong.
authors.forename: Charlotte
authors.initials: C
authors.lastname: Leung
authors.affiliation: Department of Medicine, Tuen Mun Hospital, Shatin, Hong Kong.
authors.forename: Celia
authors.initials: C
authors.lastname: Ng
authors.affiliation: Department of Medicine, Tuen Mun Hospital, Shatin, Hong Kong.
authors.forename: Yiu Ming
authors.initials: YM
authors.lastname: Yeung
authors.affiliation: Department of Medicine, Tuen Mun Hospital, Shatin, Hong Kong.
authors.forename: Sze Fai
authors.initials: SF
authors.lastname: Yip
keywords: Hodgkin disease; treatment outcome
references.citation: Haematologica. 2008 Jan;93(1):128-31
references.pmid: 18166797
references.citation: Ann Oncol. 2006 Aug;17(8):1296-300
references.pmid: 16766583
references.citation: Ann Oncol. 2010 Jun;21(6):1222-1227
references.pmid: 19901011
references.citation: Cancer. 2007 Apr 1;109(7):1360-4
references.pmid: 17326056
references.citation: Ann Hematol. 2002 Jan;81(1):20-5
references.pmid: 11807631
references.citation: N Engl J Med. 2012 Feb 2;366(5):399-408
references.pmid: 22149921
references.citation: Cancer Res. 1995 Dec 15;55(24):6012-6
references.pmid: 8521383
references.citation: Med Oncol. 2012 Jun;29(2):1127-33
references.pmid: 21390515
references.citation: J Clin Oncol. 2012 Mar 20;30(9):907-13
references.pmid: 22271480
references.citation: J Clin Oncol. 2009 Nov 10;27(32):5390-6
references.pmid: 19738111
references.citation: J Clin Oncol. 2009 Sep 20;27(27):4548-54
references.pmid: 19704068
references.citation: J Clin Oncol. 2009 Feb 10;27(5):805-11
references.pmid: 19124807
references.citation: PLoS One. 2011;6(6):e21152
references.pmid: 21695175
references.citation: Cancer Res. 1971 Nov;31(11):1860-1
references.pmid: 5121694
references.citation: Cancer. 1975 Jul;36(1):252-9
references.pmid: 54209
references.citation: Arch Med Sci. 2014 May 12;10(2):406-9
references.pmid: 24904680
references.citation: Lancet Oncol. 2010 Sep;11(9):827-34
references.pmid: 20688564
references.citation: Lancet. 2012 May 12;379(9828):1791-9
references.pmid: 22480758
references.citation: Oncology (Williston Park). 2008 Nov 15;22(12):1369-79
references.pmid: 19086599
references.citation: J Clin Oncol. 2010 Sep 20;28(27):4199-206
references.pmid: 20713848
references.citation: J Clin Oncol. 2005 Dec 20;23(36):9208-18
references.pmid: 16314615
references.citation: N Engl J Med. 2010 Aug 12;363(7):640-52
references.pmid: 20818855
references.citation: J Clin Oncol. 2011 Nov 10;29(32):4234-42
references.pmid: 21990399
references.citation: J Clin Oncol. 2003 Feb 15;21(4):607-14
references.pmid: 12586796
references.citation: Med Oncol. 2012 Jun;29(2):1237-41
references.pmid: 21556931
references.citation: J Clin Oncol. 2002 Feb 1;20(3):630-7
references.pmid: 11821442
references.citation: J Clin Oncol. 2007 Aug 20;25(24):3746-52
references.pmid: 17646666
references.citation: Diagn Pathol. 2011 Aug 22;6:77
references.pmid: 21854649
references.citation: Haematologica. 2009 Jul;94(7):998-1005
references.pmid: 19454492
references.citation: Ann Oncol. 2004 Apr;15(4):626-30
references.pmid: 15033671
references.citation: Blood. 2011 Dec 8;118(24):6292-8
references.pmid: 21917759
references.citation: Ann Hematol. 2008 Jun;87(6):481-5
references.pmid: 18299831
references.citation: J Med Virol. 2008 Jun;80(6):960-6
references.pmid: 18428141
references.citation: Hematol Oncol. 1989 Nov-Dec;7(6):395-403
references.pmid: 2807177
references.citation: Br J Haematol. 2004 Jun;125(5):584-9
references.pmid: 15147373
references.citation: N Engl J Med. 1998 Nov 19;339(21):1506-14
references.pmid: 9819449
references.citation: Am J Clin Pathol. 2012 Sep;138(3):429-34
references.pmid: 22912361
references.citation: Ann Oncol. 2003 Feb;14(2):268-72
references.pmid: 12562654
references.citation: Ann Oncol. 2011 Sep;22 Suppl 6:vi55-8
references.pmid: 21908505
references.citation: N Engl J Med. 2009 Dec 10;361(24):2390-1
references.pmid: 20007568